TRF Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 8, 2025, 6:07 pm

Quick Insight

TRF Ltd, operating in the heavy engineering industry, currently trades at a price of ₹337 with a market capitalization of ₹368 Cr. The company's P/E ratio stands at 15.1, showcasing a solid return on equity (ROE) of undisclosed percentage and a robust return on capital employed (ROCE) of 21.8%. With an operating profit margin (OPM) at 13.66% and a net profit of ₹26 Cr, TRF Ltd's capital structure reveals a high debt level of ₹554 Cr against reserves of -₹367 Cr. Shareholder distribution includes 34.12% promoters, 0.46% FIIs, 0.02% DIIs, and 65.38% public ownership spread among 26,409 shareholders. The company's price-to-book value (P/BV) ratio of 4.64x and interest coverage ratio (ICR) of 3.38x suggest potential overvaluation and moderate debt servicing capacity, respectively. In conclusion, TRF Ltd showcases strong operational efficiency and profitability metrics, but its high debt levels and valuation ratios warrant further scrutiny for investment decisions.

Competitors of TRF Ltd

All Competitor Stocks of TRF Ltd

Quarterly Result

Last Updated: August 1, 2025, 10:00 am

Below is a detailed analysis of the quarterly data for TRF Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 23.42 Cr.. The value appears to be declining and may need further review. It has decreased from 27.11 Cr. (Mar 2025) to 23.42 Cr., marking a decrease of 3.69 Cr..
• For Expenses, as of Jun 2025, the value is 20.22 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 20.88 Cr. (Mar 2025) to 20.22 Cr., marking a decrease of 0.66 Cr..
• For Operating Profit, as of Jun 2025, the value is 3.20 Cr.. The value appears to be declining and may need further review. It has decreased from 6.23 Cr. (Mar 2025) to 3.20 Cr., marking a decrease of 3.03 Cr..
• For OPM %, as of Jun 2025, the value is 13.66%. The value appears to be declining and may need further review. It has decreased from 22.98% (Mar 2025) to 13.66%, marking a decrease of 9.32%.
• For Other Income, as of Jun 2025, the value is 3.78 Cr.. The value appears to be declining and may need further review. It has decreased from 6.53 Cr. (Mar 2025) to 3.78 Cr., marking a decrease of 2.75 Cr..
• For Interest, as of Jun 2025, the value is 2.81 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 3.23 Cr. (Mar 2025) to 2.81 Cr., marking a decrease of 0.42 Cr..
• For Depreciation, as of Jun 2025, the value is 0.66 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.87 Cr. (Mar 2025) to 0.66 Cr., marking a decrease of 0.21 Cr..
• For Profit before tax, as of Jun 2025, the value is 3.51 Cr.. The value appears to be declining and may need further review. It has decreased from 8.66 Cr. (Mar 2025) to 3.51 Cr., marking a decrease of 5.15 Cr..
• For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 59.35% (Mar 2025) to 0.00%, marking a decrease of 59.35%.
• For Net Profit, as of Jun 2025, the value is 3.51 Cr.. The value appears to be declining and may need further review. It has decreased from 3.52 Cr. (Mar 2025) to 3.51 Cr., marking a decrease of 0.01 Cr..
• For EPS in Rs, as of Jun 2025, the value is 3.19. The value appears to be declining and may need further review. It has decreased from 3.20 (Mar 2025) to 3.19, marking a decrease of 0.01.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: May 15, 2025, 4:57 am

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 2:10 pm

Below is a detailed analysis of the balance sheet data for TRF Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 11.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 11.00 Cr..
• For Reserves, as of Mar 2025, the value is -367.00 Cr.. The value appears to be improving (becoming less negative). It has improved from -395.00 Cr. (Mar 2024) to -367.00 Cr., marking an improvement of 28.00 Cr..
• For Borrowings, as of Mar 2025, the value is 554.00 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 542.00 Cr. (Mar 2024) to 554.00 Cr., marking an increase of 12.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 141.00 Cr.. The value appears to be improving (decreasing). It has decreased from 151.00 Cr. (Mar 2024) to 141.00 Cr., marking a decrease of 10.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 339.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 310.00 Cr. (Mar 2024) to 339.00 Cr., marking an increase of 29.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 21.00 Cr.. The value appears strong and on an upward trend. It has increased from 19.00 Cr. (Mar 2024) to 21.00 Cr., marking an increase of 2.00 Cr..
• For CWIP, as of Mar 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 1.00 Cr., marking an increase of 1.00 Cr..
• For Investments, as of Mar 2025, the value is 20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 66.00 Cr. (Mar 2024) to 20.00 Cr., marking a decrease of 46.00 Cr..
• For Other Assets, as of Mar 2025, the value is 298.00 Cr.. The value appears strong and on an upward trend. It has increased from 225.00 Cr. (Mar 2024) to 298.00 Cr., marking an increase of 73.00 Cr..
• For Total Assets, as of Mar 2025, the value is 339.00 Cr.. The value appears strong and on an upward trend. It has increased from 310.00 Cr. (Mar 2024) to 339.00 Cr., marking an increase of 29.00 Cr..

However, the Borrowings (554.00 Cr.) are higher than the Reserves (-367.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for TRF Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 23.44. This value is within the healthy range. It has decreased from 31.45 (Mar 24) to 23.44, marking a decrease of 8.01.
• For Diluted EPS (Rs.), as of Mar 25, the value is 23.44. This value is within the healthy range. It has decreased from 31.45 (Mar 24) to 23.44, marking a decrease of 8.01.
• For Cash EPS (Rs.), as of Mar 25, the value is 25.73. This value is within the healthy range. It has decreased from 33.48 (Mar 24) to 25.73, marking a decrease of 7.75.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 75.85. It has increased from -348.54 (Mar 24) to 75.85, marking an increase of 424.39.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 75.85. It has increased from -348.54 (Mar 24) to 75.85, marking an increase of 424.39.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 109.72. It has decreased from 127.18 (Mar 24) to 109.72, marking a decrease of 17.46.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 43.17. This value is within the healthy range. It has decreased from 52.49 (Mar 24) to 43.17, marking a decrease of 9.32.
• For PBIT / Share (Rs.), as of Mar 25, the value is 40.88. This value is within the healthy range. It has decreased from 50.46 (Mar 24) to 40.88, marking a decrease of 9.58.
• For PBT / Share (Rs.), as of Mar 25, the value is 28.11. This value is within the healthy range. It has decreased from 37.86 (Mar 24) to 28.11, marking a decrease of 9.75.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 23.44. This value is within the healthy range. It has decreased from 31.45 (Mar 24) to 23.44, marking a decrease of 8.01.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 23.44. This value is within the healthy range. It has decreased from 31.45 (Mar 24) to 23.44, marking a decrease of 8.01.
• For PBDIT Margin (%), as of Mar 25, the value is 39.35. This value is within the healthy range. It has decreased from 41.26 (Mar 24) to 39.35, marking a decrease of 1.91.
• For PBIT Margin (%), as of Mar 25, the value is 37.26. This value exceeds the healthy maximum of 20. It has decreased from 39.67 (Mar 24) to 37.26, marking a decrease of 2.41.
• For PBT Margin (%), as of Mar 25, the value is 25.61. This value is within the healthy range. It has decreased from 29.77 (Mar 24) to 25.61, marking a decrease of 4.16.
• For Net Profit Margin (%), as of Mar 25, the value is 21.36. This value exceeds the healthy maximum of 10. It has decreased from 24.72 (Mar 24) to 21.36, marking a decrease of 3.36.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 21.36. This value exceeds the healthy maximum of 20. It has decreased from 24.72 (Mar 24) to 21.36, marking a decrease of 3.36.
• For Return on Networth / Equity (%), as of Mar 25, the value is 30.90. This value is within the healthy range. It has increased from -9.02 (Mar 24) to 30.90, marking an increase of 39.92.
• For Return on Capital Employeed (%), as of Mar 25, the value is 20.59. This value is within the healthy range. It has decreased from 35.72 (Mar 24) to 20.59, marking a decrease of 15.13.
• For Return On Assets (%), as of Mar 25, the value is 7.60. This value is within the healthy range. It has decreased from 11.18 (Mar 24) to 7.60, marking a decrease of 3.58.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 1.38. This value exceeds the healthy maximum of 1. It has increased from -0.24 (Mar 24) to 1.38, marking an increase of 1.62.
• For Total Debt / Equity (X), as of Mar 25, the value is 1.38. This value exceeds the healthy maximum of 1. It has increased from -0.31 (Mar 24) to 1.38, marking an increase of 1.69.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.37. It has decreased from 0.43 (Mar 24) to 0.37, marking a decrease of 0.06.
• For Current Ratio (X), as of Mar 25, the value is 2.23. This value is within the healthy range. It has increased from 1.74 (Mar 24) to 2.23, marking an increase of 0.49.
• For Quick Ratio (X), as of Mar 25, the value is 2.20. This value exceeds the healthy maximum of 2. It has increased from 1.70 (Mar 24) to 2.20, marking an increase of 0.50.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 4. It has decreased from 1.99 (Mar 24) to 0.75, marking a decrease of 1.24.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 3.38. This value is within the healthy range. It has decreased from 4.17 (Mar 24) to 3.38, marking a decrease of 0.79.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.83. This value is below the healthy minimum of 3. It has decreased from 3.86 (Mar 24) to 2.83, marking a decrease of 1.03.
• For Enterprise Value (Cr.), as of Mar 25, the value is 310.26. It has decreased from 490.88 (Mar 24) to 310.26, marking a decrease of 180.62.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.57. This value is within the healthy range. It has decreased from 3.51 (Mar 24) to 2.57, marking a decrease of 0.94.
• For EV / EBITDA (X), as of Mar 25, the value is 6.53. This value is within the healthy range. It has decreased from 8.50 (Mar 24) to 6.53, marking a decrease of 1.97.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 3.17 (Mar 24) to 3.21, marking an increase of 0.04.
• For Price / BV (X), as of Mar 25, the value is 4.64. This value exceeds the healthy maximum of 3. It has increased from -1.16 (Mar 24) to 4.64, marking an increase of 5.80.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 3.17 (Mar 24) to 3.21, marking an increase of 0.04.
• For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 24) to 0.06, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness